U.S. Markets closed
  • S&P Futures

    4,377.00
    -34.75 (-0.79%)
     
  • Dow Futures

    34,852.00
    -122.00 (-0.35%)
     
  • Nasdaq Futures

    14,840.75
    -197.00 (-1.31%)
     
  • Russell 2000 Futures

    2,222.10
    -15.40 (-0.69%)
     
  • Crude Oil

    73.16
    -0.46 (-0.62%)
     
  • Gold

    1,831.60
    -4.20 (-0.23%)
     
  • Silver

    25.58
    -0.20 (-0.78%)
     
  • EUR/USD

    1.1886
    -0.0010 (-0.0832%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3954
    -0.0004 (-0.0265%)
     
  • USD/JPY

    109.4970
    +0.0360 (+0.0329%)
     
  • BTC-USD

    40,108.23
    +292.28 (+0.73%)
     
  • CMC Crypto 200

    954.86
    +24.50 (+2.63%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,315.06
    -467.36 (-1.68%)
     

Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021

·1 min read

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2020 financial results on Thursday, February 25, 2021.

In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 25, 2021, to discuss the Company’s financial results and provide a corporate update.

Conference ID: 5764004
Domestic Dial-in Number: (833) 646-0603
International Dial-in Number: (929) 517-9782
Live Webcast: https://edge.media-server.com/mmc/p/vsbk8uqe

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210219005072/en/

Contacts

For Investors and Media:
Bryan Giraudo, Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com